文献速递妇科

界定子宫内膜癌中「肿大」前哨淋巴结:尺寸截断值是什么?

Defining "enlarged" sentinel lymph nodes in the setting of endometrial cancer: What is the size cut-off?
PubMed 文献 · Gynecol Oncol · 2025-02-18

该研究回顾性分析2017至2020年单中心接受前哨淋巴结评估的子宫内膜癌手术分期患者,比较阴性及阳性前哨淋巴结大小。阴性前哨淋巴结中位大小2.0 cm,阳性2.1 cm,尺寸≥2 cm检测转移的灵敏度67%、特异度49%,结论认为前哨淋巴结大小不能作为转移的预测指标。

要点

  • 阴性前哨淋巴结中位大小2.0 cm,阳性前哨淋巴结中位大小2.1 cm,两者相似。
  • 淋巴结尺寸≥2 cm检测转移的灵敏度67%、特异度49%。
  • 年龄<50岁及BMI≥30与淋巴结尺寸较大相关(p=0.04及p=0.028)。

核心结论

  • 阴性与阳性前哨淋巴结大小相似,前哨淋巴结大小是接受手术分期的子宫内膜癌患者转移的不良预测指标。
  • 术中评估尺寸不应作为靶向淋巴结切除的唯一指征。

研究设计与样本

  • 回顾性分析2017至2020年单中心接受前哨淋巴结评估至少一个半骨盆的手术分期子宫内膜癌患者。
  • 共597例患者,其中575例有可评估的阴性前哨淋巴结,39例有可评估的阳性前哨淋巴结。

主要发现

  • 阴性前哨淋巴结中位大小2.0 cm(范围0.4-4.5 cm),阳性前哨淋巴结中位大小2.1 cm(范围0.5-4.9 cm)。
  • 淋巴结尺寸≥2 cm检测转移的灵敏度67%、特异度49%。
  • 年龄<50岁及BMI≥30与淋巴结尺寸较大相关(p=0.04及p=0.028)。
  • 在可评估的阳性前哨淋巴结中,错配修复(MMR)免疫组化(n=39)及p53免疫组化(n=18)不影响大小(p=0.71及p=0.83)。

临床怎么用

  • 原文结论认为术中评估尺寸不应作为靶向淋巴结切除的唯一指征。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sentinel lymph node (SLN) mapping has become standard-of-care in endometrial cancer surgical staging. While removal of "enlarged" lymph nodes is recommended regardless of SLN mapping, there is no data to support definitive size criteria for intra-operative assessment. We sought to assess the size of negative and positive SLN in surgically-staged endometrial cancer patients. METHODS: Surgically-staged endometrial cancer patients undergoing SLN assessment of at least one hemipelvis at a single comprehensive cancer center were retrospectively reviewed from 2017 to 2020. SLN were categorized as negative (benign) or positive (metastatic). SLN size was defined as the largest diameter (cm) of the SLN as measured in the gross description of the surgical pathology report. Size of negative and positive SLN was compared using descriptive statistics. RESULTS: Of 597 patients, 575 had an evaluable negative SLN, and median size was 2.0 cm [0.4-4.5 cm]. 39 patients had an evaluable positive SLN, and median size was 2.1 cm [0.5-4.9 cm]. Lymph node size ≥2 cm was 67 % sensitive and 49 % specific for detecting metastatic disease. Age < 50 and BMI ≥30 were associated with larger lymph node size (p = 0.04 and p = 0.028, respectively). For evaluable positive SLN, mismatch repair (MMR) IHC (n = 39), and p53 IHC (n = 18) did not impact size (p = 0.71 and p = 0.83, respectively). CONCLUSIONS: Negative and positive SLN are similar in size, thus SLN size is a poor predictor of metastasis in patients undergoing surgical staging of endometrial cancer. Intra-operative assessment of size should not serve as sole indication for targeted lymph node removal.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Haight P, Bilbe C, Riedinger C, et al. Defining "enlarged" sentinel lymph nodes in the setting of endometrial cancer: What is the size cut-off? Gynecol Oncol. 2025. PMID: 39970634. doi:10.1016/j.ygyno.2025.02.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。